OmniAb (OABI) Q4 2024 earnings summary

Executive summary

• Achieved double-digit growth in active partners (18% YoY) and programs (12% YoY), reaching 91 partners and 363 programs as of December 31, 2024, with clinical-stage programs advancing and new technologies such as OmnidAb, OmniDeep, and OmniHub launched to drive engagement and value.

• Five new clinical programs entered the clinic in 2024, with five also exiting, resulting in flat net growth in active clinical programs; 32 programs in clinical development or commercialization as of year-end.

• Partners initiated or completed over 200 human clinical trials with OmniAb-derived programs, spanning oncology, immunology, and other indications.

• Key royalty assets and milestone opportunities are coming into focus, with over $3 billion in contracted potential milestones.

• Exceeded internal goals for key metrics and continued to optimize business scalability, maintaining a strong commitment to innovation and future growth opportunities.

Financial highlights

• Q4 2024 revenue was $10.8M, up from $4.8M in Q4 2023, driven by higher license and milestone revenue, partially offset by lower service and royalty revenue.

• Full-year 2024 revenue was $26.4M, down from $34.2M in 2023, mainly due to the absence of a $10M milestone received in 2023 and lower royalty revenue.

• Full-year 2024 net loss was $62M ($0.61/share) versus $50.6M ($0.51/share) in 2023; Q4 2024 net loss was $13.1M ($0.12/share), improved from $14.1M ($0.14/share) in Q4 2023.

• Operating expenses for 2024 were $100.9M, down from $103.6M in 2023, with R&D at $55.1M and G&A at $30.7M.

• Ended 2024 with $59.4M in cash, cash equivalents, and short-term investments.

Outlook and guidance

• 2025 revenue guidance set at $20–$25M, with cash receipts from partners expected to increase and operating expenses projected at $90–$95M.

• 2025 cash use anticipated to be lower than 2024's $38.9M (excluding ATM proceeds); effective tax rate expected to be around 0%.

• Revenue decline in 2025 attributed to lower non-cash service revenue, but continued innovation and pipeline expansion expected.